Literature DB >> 872464

Quadriceps tendon ruptures in uremia. Treatment with surgery and 1alpha-hydroxycholecalciferol.

A M Pierides, H A Ellis, P Aljama, D N Kerr.   

Abstract

Three young patients with chronic renal failure, one on regular hemodialysis, suffered bilateral quadriceps tendon ruptures. All three had uncontrolled, severe osteitis fibrosa. In two, aluminium hydroxide failed to control secondary hyperparathyroidism, while 1alpha-hydroxycholecalciferol (1alphaOHD3) given after the injury resulted in rapid resolution of the hyperparathyroidism. Prevention of tendon ruptures in uremia depends on effective control of secondary hyperparathyroidism. Treatment should involve prompt surgical repair and reversal of the osteitis fibrosa with an effective vitamin D metabolite such as 1alphaOHD3.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872464

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

Review 1.  Corticosteroid-associated tendinopathies: an analysis of the published literature and spontaneous pharmacovigilance data.

Authors:  Irene Blanco; Stephan Krähenbühl; Raymond G Schlienger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Bilateral ruptures of the extensor mechanism of the knee: A systematic review.

Authors:  Lawrence Camarda; Antonio D'Arienzo; Salvatore Morello; Marco Guarneri; Francesco Balistreri; Michele D'Arienzo
Journal:  J Orthop       Date:  2017-08-02

3.  Simultaneous avulsion of patellar apexes bilaterally in a hemodialysis patient.

Authors:  T Munakata; J Nishida; T Shimamura; S Ichinohe; M Abe; S Ehara
Journal:  Skeletal Radiol       Date:  1995-04       Impact factor: 2.199

4.  Hyperparathyroidism in renal failure.

Authors: 
Journal:  Br Med J       Date:  1978-02-18

5.  Insidious bilateral infrapatellar tendon rupture in a patient with systemic lupus erythematosus.

Authors:  L M Cooney; J M Aversa; J H Newman
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.